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Abstract
Carbon nanoparticles have recently drawn intense attention in biomedical applications. Hence, there is a need
for further in vivo investigations of their biocompatibility and biodistribution via various exposure routes. We
hypothesized that intraperitoneally injected diamond, graphite, and graphene oxide nanoparticles may have
different biodistribution and exert different effects on the intact organism. Forty Wistar rats were divided into four
groups: the control and treated with nanoparticles by intraperitoneal injection (4 mg of nanoparticles/kg body
weight) eight times during the 4-week period. Blood was collected for evaluation of blood morphology and
biochemistry parameters. Photographs of the general appearance of each rat’s interior were taken immediately
after sacrifice. The organs were excised and their macroscopic structure was visualized using a stereomicroscope.
The nanoparticles were retained in the body, mostly as agglomerates. The largest agglomerates (up to 10 mm
in diameter) were seen in the proximity of the injection place in the stomach serous membrane, between the
connective tissues of the abdominal skin, muscles, and peritoneum. Numerous smaller, spherical-shaped aggregates
(diameter around 2 mm) were lodged among the mesentery. Moreover, in the connective and lipid tissue in the
proximity of the liver and spleen serosa, small aggregates of graphite and graphene oxide nanoparticles were
observed. However, all tested nanoparticles did not affect health and growth of rats. The nanoparticles had no
toxic effects on blood parameters and growth of rats, suggesting their potential applicability as remedies or
in drug delivery systems.
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Background
Carbon nanoparticles (CNP) are a promising type of
biomaterial for diagnostic and therapeutic applications
due to their high biocompatibility and low toxicity [1, 2].
Diamond nanoparticles (DN), graphite nanoparticles
(GN), and graphene oxide (GO) are receiving increasing
attention in biomedical sciences for a large variety of ap-
plications, including protein immobilization, biosensors,
therapeutic molecule delivery, and bioimaging.
Among the chosen nanoparticles, DN have attracted
the greatest attention in in vivo experiments due to their
physicochemical properties such as chemical stability,
small size, large surface area, high adsorption capacity,
good biocompatibility [3, 4], and easy surface functiona-
lization for photostable fluorescent and luminescent im-
aging [4–7]. It has been suggested that DN may prove to
be an even better drug carrier [8], imaging probe [9, 10],
or implant coating [11] in biological systems compared
with other carbon nanomaterials. Moreover, in vivo
studies have not observed any negative effects in labora-
tory animals. DN administered to mice over 6 months
had no harmful effects on growth, fertility, immunity,
and biochemical and morphological parameters of the
blood [12–14].
In vivo toxicity of GN has not been extensively investi-
gated yet. It has been reported that graphite nanoplate-
lets had no genotoxic or in vivo toxic effects on
Caenorhabditis elegans [15].
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Recently, the potential toxicity of graphene in bio-
logical systems has become of great concern [16–18]. It
has been demonstrated that, after intravenous injection
into mice, GO accumulated in the lungs, resulting in
pulmonary edema and granuloma formation [17, 18]. In-
travitreal injection of GO into rabbits’ eyes affected the
eyeballs’ appearance, intraocular pressure, electroretino-
gram, and histological parameters [19]. On the other
hand, surface-functionalized graphene or GO with im-
proved water dispersity and better stability in physio-
logical environments appear to be much less toxic [17].
Their intrinsic physical properties such as the strong
light absorption and fluorescence of functionalized GO
and its nanocomposites have been utilized for photo-
thermal therapy of cancer and as a contrast agent for in
vitro and in vivo imaging [20, 21].
CNP have a high potential to be used as a drug carrier;
hence, there is a need to investigate various exposure
routes and confirm that a chosen platform has no toxic
impact on animal models. Local administration, like the
intraperitoneal route of CNP, is sparsely investigated, but
seems to be safe, convenient, rapid, and causing less ani-
mal stress than intravenous administration. We hypothe-
sized that after injection, CNP may have different
biodistribution and exert different effects on the intact
organism. The objective of the present study was to
evaluate the biodistribution of nanoparticles in the rat
model with particular emphasis on the gross pathology,
vascular system, and general animal condition after mul-
tiple injections of a high dose of CNP. Presented results
are the first step describing in vivo biodistribution of
CNP; the next steps will include micro- and ultrastruc-
ture examination, as well as evaluations at a molecular
level.
Methods
Nanoparticles
Nanoparticle Suspensions
DN and GN were obtained from Skyspring Nanomaterials
(Houston, TX, USA). Both nanomaterials were produced
by the explosion method and synthesized to 3–4 nm. Ac-
cording to the manufacturer, the purity of DN was >95 %
and it had a specific surface area of ~282 m2/g, while the
purity of GN was >93 % and it had a specific surface area
of 540–650 m2/g. GO were prepared from graphite nano-
particles by a modified Hummers method using natural
graphite flakes (purchased from Asbury Carbons, Asbury,
USA) in the Institute of Electronic Materials Technology
(Warsaw, Poland) [22]. In a synthesis, 5 g of graphite
was added into 600 mL of H2SO4 and 67 mL of H3PO4
acid mixture. KMnO4 (30 g) was added in portions. The
reaction was kept at 50 °C with continuous stirring for
4 h. To stop the reaction, the mixture was poured on
5 mL of deionized water, and 10 mL of H2O2 was added.
Oxidized graphite was purified by sedimentation and
centrifugation until concentrated suspension had pH 7.
In the next step, the suspension was diluted with deion-
ized water to 250 mL and was subjected to sonication
by 500 W ultrasound processor with 75 % amplitude for
5 min. Dry powder was obtained via freeze-drying
process. The diameters of the GO particles ranged from
8 to 25 nm. The physical characteristics of the nanopar-
ticles are given in Table 1.
The nanoparticle powders were suspended in sterile
saline solution to a concentration of 500 mg/L and
sonicated at 550 W/m2 for 1 h in an ultrasonic bath
(Sonorex Super RK 514H, Bandelin Electronic, Germany)
before each injection.
Visualization of Nanoparticles
The size and shape of nanoparticles were inspected
using transmission electron microscopy (TEM: JEM-
2000EX; JEOL, Tokyo, Japan) at 80 keV. Images were
captured with a Morada 11 megapixel camera (Olympus
Soft Imaging Solutions GmbH, Münster, Germany).
Droplets of sample solutions were placed onto Formvar-
coated copper grids (Agar Scientific, Stansted, UK), and
immediately after air-drying, the grids were inserted into
the TEM (Fig. 1a–c). The macroscopic structure of the
nanoparticle powders was visualized using a Nikon
D7000 digital camera with a Nikon AF-S Micro-Nikkor
105mm f/2.8G IF-ED VR lens (Nikon, Tokyo, Japan)
(Fig. 1d–f ).
The DN (Fig. 1a) and GN (b) had a spherical shape.
The DN powder was cinnamon brown (d), while the GN
powder was the darkest and mostly fine-grained (e). The
shape of GO was an irregular single layer (c), and the
powder was dark brown (f).
Zeta Potential Measurements
The Zeta potential and size distribution of suspended
nanoparticles were determined after 120 s of stabilization
at 25 °C by the dynamic laser scattering-electrophoretic
method with Smoluchowski approximation by Zetasizer
Nano-ZS90 (Malvern, Worcestershire, UK). Each meas-
urement was repeated three times. The mean Zeta
Table 1 Summary of the physical and chemical properties of
diamond (DN), graphite (GN), and graphene oxide (GO)
nanoparticles
DN GN GO
Shape Spherical Spherical Irregular
Average size (nm) 3–4 3–4 8–25
Zeta potential (mV) −15.8 ± 0.55 12.5 ± 0.43 −8.8 ± 0.25
Shape was estimated upon analysis of transmission electron microscopy
pictures. Zeta potential and average size were measured by a Zetasizer. The
results are means ± standard deviation
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potentials of the DN, GN, and GO solutions in 0.9 % NaCl
were −15.8, 12.5, and −8.80 mV, respectively (Table 1).
Animals
Animal Maintenance
The experiments were performed in accordance with
Polish legal regulations concerning experiments on ani-
mals (Dz. U. 05.33.289). The experimental protocols
were approved by the local ethics commission for ex-
perimentation on animals.
Forty female Wistar/cmdb outbred rats (6 weeks
old, 124 ± 12 g body weight (BW)) were randomly di-
vided into four groups (control, DN, GN, GO) and
kept in polycarbonate cages with steel wire tops. They
were kept under standard conditions at a room
temperature of 22 ± 2 °C, 50–60 % humidity, and 12:12
light-dark cycle (lights on at 7 a.m.).
The animals had free access to water and dry pellet
feed (Labofeed B standard, Wytwórnia Pasz ‘Morawski’,
Poland). During the whole experiment, animal behavior
and hair/skin condition were monitored.
Administration of Nanoparticles
Rats received multiple intraperitoneal injections of 1 mL
of physiological saline (0.9 % NaCl) for the control (pla-
cebo) group and 1 mL of nanoparticle suspensions in
physiological saline for the treatment groups. The injec-
tions were given for 4 weeks at 3-day intervals (eight
injections in total). The nanoparticle suspensions were
given at a concentration of 500 mg/L, equivalent to
4 mg of nanoparticles/kg BW.
Animal Euthanasia
After 4 weeks of CNP injection, the rats were fasted
overnight prior to blood collection. The animals were
euthanized by inhalation of isoflurane (Forane, USP, Baxter
Poland). The anesthetized animals were laid in dorsal re-
cumbency during the cardiac puncture procedure, which
was used to collect blood samples from the heart. Blood
was collected for evaluation of blood morphology and bio-
chemistry parameters. Photographs of the general appear-
ance of each rat’s interior were taken immediately after
sacrifice.
Weight Changes and Organ Indices
Individual rats were weighed at the beginning of experi-
ment, prior to every injection and shortly before euthan-
asia. The mean BW of the groups was plotted against
time to reveal the course of BW gain. The rats were
sacrificed and their organs were excised and weighed.
The macroscopic structure of the organs was visualized
using a stereomicroscope (Olympus, SZX 10, Tokyo,
Japan).
Biochemical Serum Parameters and Hematology
Measurements
Blood was collected in 5 mL tubes with a coagulation ac-
tivator and 1 mL tubes with K3-EDTA. All biochemical
parameters were assessed using a Miura One Clinical
Chemistry Analyzer (I.S.E., Guidonia, Italy), and the
reagents were purchased from Pointe Scientific Inc.
(Canton, USA). Blood collected in the tubes with a co-
agulation activator was centrifuged at 3800 × g for
Fig. 1 Nanoparticles visualized using transmission electron microscopy (a–c) and a digital camera (d–f). Images of diamond (a) and (d), graphite
(b) and (e), and graphene oxide (c) and (f)
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8 min at 4 °C for hemolysis-free serum collection. The
biochemistry of the hemolysis-free serum was analyzed
by standard laboratory procedures. The following pa-
rameters were examined: aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phos-
phatase (ALP), glucose, creatinine, blood urea nitrogen
(BUN), total protein (TP), albumin, lactate dehydro-
genase (LDH), and triglycerides (TG).
Blood collected in the tubes with K3-EDTA was used for
hematology examination, performed with an Abacus Junior
Vet Hematologic Analyzer (Diatron Group, Budapest,
Hungary). The following parameters of the whole blood
were examined: number of red blood cells (1012/L), plasma
hemoglobin concentration (g/dL), hematocrit (%), number
of platelets (109/L), relative distribution width of the red
cell population (% of covariance), red cell mean corpuscu-
lar volume (fL), mean erythrocyte hemoglobin concentra-
tion (pg), and mean cell hemoglobin concentration (g/dL).
White blood cell subpopulations were quantified and
expressed in absolute numbers (109/L): white blood cells,
lymphocyte counts, granulocyte counts, and mid cell
counts. The mean platelet volume (fL) and plateletcrit/rela-
tive volume of thrombocytes (%) were also determined.
Data Analysis
Statistical significance was determined by one-way ana-
lysis of variance (ANOVA) and Tukey’s test using Stat-
graphics® Plus 4.1 (StatPoint Technologies, Warrenton,
VA, USA). Differences at P ≤ 0.05 were defined as statis-
tically significant. All data are presented as mean ±
standard deviation.
Results
Animals’ Body Condition/General Health Status
During the 4 weeks of injections, none of the animals
showed physical or behavioral changes. Daily intake of
feed and water and BW gain did not differ significantly
between the groups (Figs. 2 and 3).
Macroscopic Evaluation of Organs
During macroscopic evaluation of the organs, no
pathological changes were observed (Figs. 4f–j, 5f–j,
6f–j, and 7d–h). There were no significant differences
in the mean organ weights between any of the groups
(Table 2).
Accumulation of nanoparticles was noticeable in the
body tissues of all CNP-treated groups (Figs. 4a–e, 5a–e, i,
6a–e, 8, and 9). The largest solid aggregates (up to 10 mm
in diameter) were in the proximity of the injection site in
the stomach serous membrane, between the connective
tissues of the abdominal skin, muscles, and peritoneum
(Figs. 4a–c, 5a–c, 6a–c, and 8). Numerous smaller,
spherical-shaped aggregates (diameters around 2 mm)
were lodged among the mesentery, to a lesser extent in
DN (Fig. 4d) than in the GN (Fig. 5d) and GO (Fig. 6d)
groups, where the mesenteries were almost black due to
their burden of nanoparticles. Smaller aggregates were ob-
served in abdominal lipid tissue in the proximity of the in-
jection site and mesentery (Figs. 4e, 5i, 6e, and 8).
Moreover, in connective and lipid tissue in the proximity
of the spleen serosa, small aggregates of GN (Fig. 5i) and
GO (Fig. 9a, 9b) were observed. Most of them were small
dots (<1 μm in diameter) formed in groups (around 2 mm
in diameter), which could be the beginning of a process
forming larger aggregates. In the proximity of connective
and lipid tissue in the liver serosa, small aggregates (up to
1 mm in diameter) and dots (up to 1 μm in diameter)
were observed in the GN group (Fig. 9c, d). No CNP ag-
gregates were found in the kidneys, suggesting that CNP
aggregates were unable to penetrate to retroperitoneal or-
gans through adventitia. In the control group, there were
no pathological changes surrounding the injection region
Fig. 2 Average daily intake of dry pellet feed (a) and water (b) during 4 weeks per rat. Data presented are the average of multiple determinations
(n = 10), with error bars representing the mean standard deviation
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(Fig. 7a, b) or among the mesentery (Fig. 7c). Moreover,
the control group mesentery was much better supplied
with blood and had larger blood vessels than in the CNP
groups.
Biochemical Serum Parameters and Hematology
To assess the systemic toxicity of CNP, a number of
biochemical parameters in serum, such as aspartate ami-
notransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP), blood urea nitrogen (BUN),
total protein, lactate dehydrogenase, triglycerides, albu-
mins, and creatinine were measured (Table 3). In the
present study, liver function was evaluated by measuring
the serum levels of AST, ALT, ALP, and creatinine.
Kidney function was evaluated by analysis of the BUN
and creatinine values in serum. Most of the examined
biochemical parameters in blood serum did not show
significant differences in comparison to the control
group. However, ALP and creatinine were significantly
different in the GN group compared to the control
Fig. 3 Body weight (BW) gain in rats during 4 weeks. Data presented
are the average of multiple determinations (n = 10), with error bars
representing the mean standard deviation
Fig. 4 Visualization by digital camera of the biodistribution of diamond nanoparticles after multiple intraperitoneal injections into rats. Solid
aggregates were lodged in injected body regions (a, b, c), small dots of nanoparticle aggregates were also present in abdominal lipid tissue
(e) and mesentery (d). Black arrows indicate diamond nanoparticle aggregates. The macroscopic structure of the kidney (f), lungs (g), heart
(h), spleen (i), and liver (j) were also examined. There were no macroscopic pathological features on the organs
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group. In all groups, the level of glucose in blood serum
was significantly lower than in the control group. These
results indicate that GN exposure could induce toxico-
logical effects on the liver and kidney, but DN and GO
had no effects.
To assess the biocompatibility of CNP, chosen
hematological parameters were measured (Table 4). The
present results were compared with reference intervals for
hematological parameters in diet-restricted 8 to 16-week-
old Wistar rats collected under isoflurane anesthesia for
female provided by Charles River Laboratories (Senneville,
Canada). Most of the hematological parameters remained
within the reference range, but the number of red blood
cells, hemoglobin, hematocrit, and mean cell hemoglobin
concentration dipped slightly when relative distribution
width of the red cell population slightly exceed up.
Discussion
In the present experiment, we chose a relatively high dose
(4 mg/kg BW) and multiple intraperitoneal injections
(eight times) of nanoparticles to evaluate potential harm-
ful effects on animal growth and health status. Since CNP
are very small, we expected that it would be difficult to
observe their distribution in animal organs by conven-
tional microscopy, but surprisingly, DN, GN, and GO
formed agglomerates that could be seen even by the naked
human eye (Figs. 4a–e, 5a–e, i, 6a–e, 8, and 9). Probably
because CNP are hydrophobic and aggregate readily, it is
difficult to disperse them in living organisms. We did not
observe any signs of inflammation, necrosis, or tissue re-
action in the vicinity of injections. None of the excised or-
gans showed any abnormalities after CNP administration
(Figs. 4f–j, 5f–j, and 6f–j). It should also be noted that feed
intake and body gain were not significantly different
between any of the groups.
The majority of CNP aggregates were positioned
around the injection region, while only small CNP dots
were among the mesentery (DN, GO, GN) and in the
proximity of the spleen (GN, GO) and liver (GN) serosa.
There was no evidence of CNP being present in the
Fig. 5 Visualization of the biodistribution of graphite nanoparticles after multiple intraperitoneal injections to rats by digital camera. Solid
aggregates were placed in injection body regions (a, b, c, e) and in mesentery (d), small dots of nanoparticle aggregates were in lipid tissue
proximity spleen serosa (i). Black arrows indicate graphite nanoparticles aggregates. The macroscopic structure of the kidney (f), lungs (g), heart
(h), spleen (i), and liver (j) were also examined. There were no macroscopic pathological features on the organs
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kidney, lungs, heart, and their surroundings. It was pre-
viously reported that nanodiamond (ND) administered
by intratracheal instillation were distributed mainly in
the spleen, liver, bones, heart, and lungs [23] (Table 5).
However, in mice intratracheally instilled with even a
higher dose (20 mg/kg) than in our experiments
(4 mg/kg), no ND were found in the liver and spleen [12].
This difference may be due to the different sources and
production methods of ND. In another work by Yuan et
al. [24], the distribution of ND after intravenous injection
was studied in mice by using 125I-labeled ND. The stability
of 125I-ND was greater than 90 % within 25 h, and the in
vivo distribution showed that ND predominantly accumu-
lated in the liver, spleen, and lung. About 60 % of the
injected ND was found in the mouse liver at 0.5 h post in-
jection, and this level stayed constant over 28 days [24].
Rojas et al. [13] labeled DN with another radionuclide, 18F,
to study their in vivo biodistribution. The results
showed that the intravenously injected DN were
mainly distributed in the lung, spleen, and liver, and
excreted into the urinary tract. Their research further
indicated that the addition of surfactant agents did
not change this distribution pattern significantly, ex-
cept for a slight reduction in the urinary excretion
rate of DN. It was also found that after removing DN
with a larger particle size by filtration, uptake of DN
was completely inhibited in the lung and spleen and sig-
nificantly reduced in the liver [13]. 60Co-Co/graphitic-shell
nanocrystals (60Co-Co/GC) were accumulated in mouse
lung, liver, and spleen at 1, 6, 12, 18, and 24 h after intra-
venous injection, with the highest accumulation at 6 h but
a low distribution in other tissues at all times. Moreover,
60Co-Co/GC began to eliminate slowly from lung and
liver after 6 h, but there was a gradual increase in the
spleen from 12 to 24 h [25]. However, it was reported that
feeding of suspensions and microinjection of fluorescent
ND into the gonads of C. elegans causes no harm [26].
Furthermore, there was no significant microscopic dif-
ference between the fluorescent ND-treated and con-
trol groups except for the presence of carbon-laden
Fig. 6 Visualization of the biodistribution of graphene oxide nanoparticles after multiple intraperitoneal injections into rats by digital camera.
Solid aggregates were found in injected body regions (a, b, c) and mesentery (d). Average-sized dots of graphene oxide nanoparticle aggregates
were also localized in abdominal lipid tissue (e). Black arrows indicate graphene oxide nanoparticle aggregates. The macroscopic structure of the
kidney (f), lungs (g), heart (h), spleen (i), and liver (j) were also examined. There were no macroscopic pathological features on the organs
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macrophage clusters on the peritoneal surface of the
ND-treated animals [27]. Likewise, single-walled car-
bon nanotubes remained in the liver and spleen for
over 3 months after intravenous injection [28]. Similar
results and administration routes were reported for
multi-walled carbon nanotubes (MWCNT). Tween 80-
dispersed MWCNT accumulated in the liver and spleen
with a short blood circulation time [27]. The simply dis-
persed MWCNT were easily recognized by macrophages
and cleared from the blood very fast, and this characteris-
tic limits their application for drug delivery [29]. In all re-
ports of CNP biodistribution, the liver and spleen are
listed as places where the nanoparticles are present but
also, depending on the administration route, nanoparticles
were encountered in lung, bones, and heart (Table 5). The
present results also identified the liver and spleen serosa
as places where nanoparticles were present, but after mul-
tiple intraperitoneal injections into rats, solid aggregates
were found mainly in proximity to the injection site in the
stomach serous membrane among the mesentery
(Figs. 4a–c, 5a–c, 6a–c, and 8). We observed that, al-
though CNP have good biocompatibility [30–32], they still
represent a foreign non-degradable material for biological
organisms. The present results and references (Table 5)
indicate that the distribution of CNP in vivo involves the
blood circulation for systemic translocation of CNP and
for the mononuclear phagocyte system (MPS) to remove
CNP from the blood. Based on the present results, we
Fig. 7 Ex vivo digital camera images of 0.9 % NaCl solution biodistribution after multiple intraperitoneal injections into rats in the placebo group.
There were no pathological changes in injected body regions (a, b) or in the mesentery (c). The macroscopic structures of the kidney (d), lungs
(e), heart (f), spleen (g), and liver (h) showed no toxic impact of physiological saline solution injection
Table 2 Mean organ weight (g/100 g of body weight) of the
control group and groups treated with diamond (DN), graphite
(GN), and graphene oxide (GO) nanoparticles
DN GN GO Control ANOVA
P value
Brain 0.83 ± 0.061 0.86 ± 0.076 0.74 ± 0.111 0.77 ± 0.117 0.494
Heart 0.34 ± 0.077 0.30 ± 0.024 0.29 ± 0.010 0.33 ± 0.020 0.405
Spleen 0.20 ± 0.028 0.25 ± 0.013 0.22 ± 0.036 0.25 ± 0.097 0.292
Kidney 0.45 ± 0.085 0.41 ± 0.043 0.41 ± 0.071 0.46 ± 0.050 0.540
Liver 4.22 ± 0.876 4.34 ± 0.427 3.95 ± 0.423 4.58 ± 0.198 0.744
The results are means of multiple determinations (n = 6) with ± standard
deviation
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propose a scheme regarding the fate of CNP in vivo after
intraperitoneal injection (Fig. 10).
The blood circulation is the vehicle for CNP systemic
translocation and tissue distribution. Upon administra-
tion, the blood circulation is presumably the first barrier
against carbon nanoparticles, which means that blood
cells have primary responsibility for governing carbon
nanoparticle trafficking and systemic translocation. We
investigated whether CNP could pose side effects to
blood cells after intraperitoneal injection. Our data con-
firmed previous results by Qu et al. [33] that CNP do
not exert acute toxicity on blood cells, which might
be partly due to rapid clearance of nanoparticles from
the circulation. However, Puzyr et al. [34] reported
toxic effects on blood parameters after intravenous
injection of RUDDM (Real-Dzerzhinsk ultra-disperse
diamond modified) to rabbit.
The mesentery blood circulation leads to the liver,
where the superior mesenteric vein and the splenic vein
come together to form the hepatic portal vein. The liver
is the primary organ for detoxification, defending living
organisms against toxic agents; hence, it is often used in
tests of the toxicity of nanomaterials [35]. Because of
CNPs localizing in the liver serosa, biochemical parame-
ters of blood serum (AST, ALT, and creatinine) reflect-
ing hepatic injury were measured. The data obtained
from the hepatotoxicity biomarker study clearly showed
that GN significantly increased the activity of serum
ALP and creatinine compared to the control group.
However, there were no abnormalities or toxic impacts
Fig. 8 Visualization of CNP aggregates under a stereomicroscope after multiple intraperitoneal injections. Diamond (a), graphite (b), and graphene
oxide (c) nanoparticles accumulated in a similar way; large aggregates up to 10 mm and small dots around 1 μm were formed. Black arrows indicate
CNP aggregates
Fig. 9 Visualization of CNP aggregates in the proximity of collected organs by stereomicroscopy. In the connective and lipid tissue of the spleen
serosa, small dots (1 μm), and groups (up to 2 mm) of graphene oxide nanoparticle aggregates were formed (a) and (b). Small dots (1 μm),
groups (up to 2 mm), and aggregates (up to 1 mm) of graphite nanoparticles were formed in the connective and lipid tissue of the liver serosa
(c) and (d). Black arrows indicate CNP aggregates
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of DN and GO on rat liver. The results from the litera-
ture are conflicting. Measurements of tissue morphology
and biochemical parameters in mice treated intratrache-
ally with DN indicated dose-dependent toxicity to the
lung, liver, kidney, and blood [23]. In contrast, Puzyr et
al.[34] found no indications of inflammatory processes
3 months after subcutaneous exposure to RUDDM in
mice, but when studied in rabbits, a number of blood
biochemical parameters were affected after intravenous
administration of RUDDM, suggesting that the exposure
route could influence the toxic effects of RUDDM.
In the connective and lipid tissue in the proximity of
the liver and spleen serosa, small aggregates of GN
(Figs. 5i and 9c, d) and GO (Fig. 9a, b) were observed.
As macrophages are highly concentrated in the liver and
spleen, it could be possible for large numbers of GN and
GO nanoparticles to accumulate in the liver and spleen
serosa and in the stomach serous membrane. Such an
uptake mechanism involving the mononuclear phagocyte
system (MPS) is consistent with the general conception
of the fate of nanoparticles in vivo [25]. The MPS re-
cognizes nanomaterials through the binding of serum
Table 3 Mean biochemical parameters of blood serum from the control group and groups treated with diamond (DN), graphite
(GN), and graphene oxide (GO) nanoparticles
DN GN GO Control ANOVA
P value
AST (IU/L) 353.7 ± 165.45 403.4 ± 169.31 363.4 ± 174.53 273.0 ± 193.34 0.861
ALT (IU/L) 89.0 ± 37.46 102.2 ± 43.10 113.5 ± 72.89 123.3 ± 70.19 0.763
ALP (IU/L) 183.1a ± 42.44 285.1b ± 61.57 182.8a ± 25.74 175.5a ± 25.08 0.000
Glucose (mg/dL) 145.7 b ± 32.89 138.1b ± 19.78 144.4b ± 24.59 218.8a ± 56.77 0.003
Creatinine (mg/dL) 0.36a ± 0.205 0.29b ± 0.147 0.49a ± 0.098 0.54a ± 0.100 0.023
BUN (mg/dL) 49.4 ± 4.37 55.3 ± 10.16 50.9 ± 5.16 53.2 ± 11.29 0.634
TP (g/L) 57.2 ± 3.06 55.3 ± 3.33 55.3 ± 5.57 59.0 ± 5.22 0.440
Albumin (g/L) 48.5 ± 4.04 48.2 ± 3.60 49.8 ± 5.27 49.8 ± 5.19 0.882
LDH (U/L) 1496 ± 420.7 1468 ± 313.3 1516 ± 297.3 1209 ± 463.5 0.481
TG (mg/dL) 135.4 ± 34.97 99.6 ± 30.18 117.1 ± 24.63 103.4 ± 26.48 0.175
The results are means of multiple determinations (n = 6) with ± standard deviation
a,bValues with different superscripts are significantly different (P ≤ 0.05)
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, BUN blood urea nitrogen, TP total protein, LDH lactate dehydrogenase,
TG triglycerides
Table 4 Mean hematologic parameters of the whole blood of rats
Parameters DN GN GO Placebo ANOVA
P value
White blood cells (109/L) 3.01 ± 1.748 3.08 ± 1.715 2.03 ± 1.179 3.13 ± 1.496 0.586
Lymphocytes (109/L) 2.65 ± 1.592 2.56 ± 1.473 1.75 ± 1.059 2.32 ± 0.665 0.622
Monocytes (109/L) 0.08 ± 0.059 0.10 ± 0.049 0.06 ± 0.043 0.09 ± 0.033 0.309
Granulocytes (109/L) 0.29 ± 0.207 0.43 ± 0.259 0.22 ± 0.104 0.73 ± 1.146 0.515
Red blood cells (1012/L) 6.67 ± 0.729 6.23 ± 0.674 5.88 ± 1.018 6.43 ± 0.813 0.440
Hemoglobin (g/dL) 11.8 ± 1.10 11.0 ± 1.29 10.7 ± 2.00 11.6 ± 1.33 0.576
Hematocrit (%) 36.30 ± 3.61 33.5 ± 3.59 32.5 ± 6.33 36.7 ± 4.06 0.392
Mean red blood cell volume (fL) 54.5 ± 2.88 54.0 ± 3.37 55.0 ± 2.10 57.2 ± 3.49 0.368
Mean cell hemoglobin (pg) 17.8 ± 0.40 17.7 ± 0.44 18.2 ± 0.40 18.1 ± 0.61 0.368
Mean cell hemoglobin concentration (g/dL) 32.7 ± 1.35 32.9 ± 1.86 33.0 ± 1.03 31.6 ± 1.18 0.336
Red blood cell distribution width (%) 15.3 ± 0.92 15.1 ± 0.82 15.0 ± 0.35 15.6 ± 1.57 0.790
Platelets (109/L) 426 ± 62.7 570 ± 383.0 691 ± 127.8 513 ± 157.5 0.455
Plateletcrit (%) 0.26 ± 0.126 0.33 ± 0.181 0.63 ± 0.487 1.68 ± 2.282 0.210
Mean platelet volume (fL) 7.3 ± 0.26 6.1 ± 0.88 6.0 ± 0.98 6.4 ± 0.75 0.065
Units are in brackets. The results are means of multiple determinations (n = 6) with ± standard deviation
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Table 5 Summary of carbon nanoparticles in vivo accumulation with emphasis on exposure routes
Nanoparticles Original nanoparticle name Exposure route Investigated animal Nanoparticles present in organs Reference
Graphene PEGylated nanographene
sheets wih Cy7
Intravenous BALB/c mice Kidney and excreted in urine [16]
Graphene oxide 125I-nGO-PEG Intraperitoneal BALB/c mice Liver, spleen [17]
125I-RGO-PEG
125I-nRGO-PEG
Graphene oxide 125I-nGO-PEG Intragastrically BALB/c mice Stomach, intestine [17]
125I-RGO-PEG
125I-nRGO-PEG
Graphene oxide 125I-nGO-PEG Intravenous BALB/c mice Liver, spleen [18]
125I-RGO-PEG
125I-nRGO-PEG
Graphene oxide Graphene oxide Intravenous BALB/c mice Lungs, liver [33]
Graphene oxide Graphene oxide + Tween 80 Intravenous BALB/c mice Liver [33]
Graphene oxide GO Intravitreal Japanese white
rabbit
Eyeball [19]
Graphene oxide 125I-NGS-PEG Intravenous BALB/c mice Liver, spleen, and excreted in urine [39]
Graphite
nanoparticles
60Co-Co/graphitic-shell nanocrystals Intravenous Kongming white
mice
Liver, lungs, spleen [25]
Graphite
nanoparticles
Graphite nanoparticles Intragastrically Caenorhabditis
elegans
Along the nematode body [15]
Multi-walled
carbon nanotubes
MWCNT Intraperitoneal Swiss-Webster mice Liver [35]
Multi-walled
carbon nanotubes
125I-tau-MWNTs Intravenous Kunming mice Liver, lungs, spleen [27]
Multi-walled
carbon nanotubes
125I-Tween-MWNTs Intravenous Kunming mice Liver, lungs, spleen, stomach, kidney,
large and small intestine
[27]
Nanodiamond 188Re-NDs Intratracheal Kun Ming mice Bones, heart, liver, lungs, spleen [23]
Nanodiamond NDs-4 Intratracheal ICR mice Lungs [12]
NDs-50
Nanodiamond 125I-NDs Intravenous ICR mice Liver, lungs, spleen [24]
Nanodiamond 18F-DNPs Intravenous Sprague-Dawley rats Liver, lungs, spleen and excreted in
urine
[13]
Nanodiamond 18F-DNPs Intravenous Swiss CD1 mice Liver, lungs, spleen and excreted in
urine
[13]
Nanodiamond NDX (nanodiamond + DOX) Intravenous Sprague-Dawley rats
BALB/c mice
Liver [4]
Nanodiamond DNX (nanodiamond + DOX) Intravenous Sprague-Dawley rats
BALB/c mice
Lungs [4]
Nanodiamond RUDDM (Real-Dzerzhinsk ultra-
disperse diamond modified)
Intravenous Chinchilla rabbits No aggregates but effects on
biochemical blood parameters
[34]
Nanodiamond RUDDM (Real-Dzerzhinsk ultra-
disperse diamond modified)
Subcutaneous ICR mice Subcutaneous injection region, skin [34]
Nanodiamond Fluorescent nanodiamond Gonad arms Caenorhabditis
elegans
Gonad, oocytes, early embryos [26]
Nanodiamond Fluorescent nanodiamond Intragastrically Caenorhabditis
elegans
Gut (digestive track, after 20 min FND
were excreted)—aggregates
[26]
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opsonin proteins to nanomaterials [33, 36]. It has been
reported that carbon nanotubes were trapped by the
MPS and retained mainly in the liver of mice for a long
time [35, 36]. GO accumulated in the liver, with most
GO aggregates localized within Kupffer cells, while no
GO could be found in hepatocytes, highlighting the im-
portant role of MPS in clearing GO from the circulation
[33]. CNP trapped in Kupffer cells could be excreted via
bile, but the process is very slow [28].
It is thought that nanoparticles should have final
hydrodynamic diameters ≤5.5 nm in order to be ex-
creted from the rat body through the kidneys [37, 38]. In
the present work, no CNP were found in the kidneys,
suggesting that CNP aggregates and agglomerates were
unable to penetrate the glomerular basement membrane.
This might be attributed to the inability of larger parti-
cles, such as the examined nanoparticles, to cross the
basement membrane. It has been demonstrated that
PEGylated GO could speed up renal excretion of small
marked nanoparticles [39]. Furthermore, there were no
CNP aggregates in the kidneys, implying that GO could
be rapidly eliminated through kidney filtration [33]. It is
highly probably that single nanoparticles of DN and GN
(3–4 nm) could be extracted by kidney, but larger CNP
are not excreted in urine; instead, they are eliminated
from the blood by the MPS and thus tend to accumulate
in the spleen and liver [37, 40, 41]. Aggregation of nano-
particles could influence their ability to interact with or
enter cells and thus adds complexity to the system [37].
In the present work, we did not observe the occurrence
of DN, GN, or GO aggregation in the kidneys; probably,
the agglomerates were not able to penetrate to retroperi-
toneal organs through adventitia.
Conclusions
The tested nanoparticles had no toxic effects on gen-
eral animal health status, growth, overall appearance
of the animal interior, organ weight, and biochemical
and hematological parameters. The CNP accumulated
as small dots (<1 μm in diameter) and massive ag-
glomerates (up to 10 mm in diameter) in proximity
to the injection sites. The tendency of CNP to form
agglomerates is unique and could be useful in drug
delivery systems to immobilize CNP and drug com-
plexes in the targeted body regions and then slowly
release active substance.
Table 5 Summary of carbon nanoparticles in vivo accumulation with emphasis on exposure routes (Continued)
Nanodiamond Dextran-coated Fluorescent
nanodiamond BSA-coated FND
Intragastrically Caenorhabditis
elegans
Intestinal cells [26]
Single-walled
carbon nanotubes
SWCNTs Intravenous CD-ICR mouse Liver, lung, spleen [28]
Single-walled
carbon nanotubes
64Cu-labeled SWNT–PEG2000 Intravenous Nude mice Liver, kidney, spleen, intestine, lung [36]
SWNT–PEG5400
Fig. 10 Carbon nanoparticles’ fate in vivo after intraperitoneal injection. CNP aggregates were observed in the proximity of the injection site in
the stomach serous membrane and localized among the mesentery. The mesentery blood circulation system governed carbon nanoparticle
trafficking and systemic translocation. The superior mesenteric vein and the splenic vein come together to form the hepatic portal vein and
transport CNP to the liver and spleen, which are mononuclear phagocyte system (MPS) organs. This uptake mechanism involves macrophages
in snatching up CNP from blood vessels
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